CD274 and non-small cell lung carcinoma: The most recent updated follow-up data from the study, which was conducted for a period of 2 years, further validates the prolonged survival benefit of dual immunotherapy combinations with chemotherapy for NSCLC, and 2-year OS and PFS benefits persisted regardless of PD-L1 expression and histological types.[64]